Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

GlobeNewswire 8 days ago

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 10 days ago

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire April 29, 2024

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

GlobeNewswire April 25, 2024

Aquestive Therapeutics to Present Crossover Study Data for Libervant(TM) (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

GlobeNewswire April 12, 2024

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

GlobeNewswire April 1, 2024

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

GlobeNewswire March 25, 2024

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

GlobeNewswire March 19, 2024

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire March 19, 2024

Aquestive Therapeutics Announces Pivotal Study for Anaphylm(TM) (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

GlobeNewswire March 14, 2024

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 5, 2024

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

GlobeNewswire February 21, 2024

Aquestive Therapeutics to Present Anaphylm(TM) (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

GlobeNewswire February 15, 2024

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

GlobeNewswire January 30, 2024

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire December 5, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm(TM) at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

GlobeNewswire November 10, 2023

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 6, 2023

Aquestive Therapeutics Completes $45 Million Debt Refinancing

GlobeNewswire November 2, 2023

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

GlobeNewswire October 31, 2023

Aquestive Therapeutics Provides Business Update

GlobeNewswire October 9, 2023